176 related articles for article (PubMed ID: 29761849)
1. MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism.
Stroopinsky D; Rajabi H; Nahas M; Rosenblatt J; Rahimian M; Pyzer A; Tagde A; Kharbanda A; Jain S; Kufe T; Leaf RK; Anastasiadou E; Bar-Natan M; Orr S; Coll MD; Palmer K; Ephraim A; Cole L; Washington A; Kufe D; Avigan D
J Cell Mol Med; 2018 Aug; 22(8):3887-3898. PubMed ID: 29761849
[TBL] [Abstract][Full Text] [Related]
2. HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML.
Li Z; Wang F; Tian X; Long J; Ling B; Zhang W; Xu J; Liang A
J Exp Clin Cancer Res; 2021 Jun; 40(1):210. PubMed ID: 34167558
[TBL] [Abstract][Full Text] [Related]
3. MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells.
Yin L; Wu Z; Avigan D; Rosenblatt J; Stone R; Kharbanda S; Kufe D
Blood; 2011 May; 117(18):4863-70. PubMed ID: 21422470
[TBL] [Abstract][Full Text] [Related]
4. MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia.
Tagde A; Rajabi H; Stroopinsky D; Gali R; Alam M; Bouillez A; Kharbanda S; Stone R; Avigan D; Kufe D
Oncotarget; 2016 Jun; 7(26):38974-38987. PubMed ID: 27259275
[TBL] [Abstract][Full Text] [Related]
5. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.
Stroopinsky D; Rosenblatt J; Ito K; Mills H; Yin L; Rajabi H; Vasir B; Kufe T; Luptakova K; Arnason J; Nardella C; Levine JD; Joyce RM; Galinsky I; Reiter Y; Stone RM; Pandolfi PP; Kufe D; Avigan D
Cancer Res; 2013 Sep; 73(17):5569-79. PubMed ID: 23867470
[TBL] [Abstract][Full Text] [Related]
6. MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.
Liu S; Yin L; Stroopinsky D; Rajabi H; Puissant A; Stegmaier K; Avigan D; Kharbanda S; Kufe D; Stone R
Blood; 2014 Jan; 123(5):734-42. PubMed ID: 24282218
[TBL] [Abstract][Full Text] [Related]
7. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.
Paczulla AM; Rothfelder K; Raffel S; Konantz M; Steinbacher J; Wang H; Tandler C; Mbarga M; Schaefer T; Falcone M; Nievergall E; Dörfel D; Hanns P; Passweg JR; Lutz C; Schwaller J; Zeiser R; Blazar BR; Caligiuri MA; Dirnhofer S; Lundberg P; Kanz L; Quintanilla-Martinez L; Steinle A; Trumpp A; Salih HR; Lengerke C
Nature; 2019 Aug; 572(7768):254-259. PubMed ID: 31316209
[TBL] [Abstract][Full Text] [Related]
8. MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs.
Pyzer AR; Stroopinsky D; Rosenblatt J; Anastasiadou E; Rajabi H; Washington A; Tagde A; Chu JH; Coll M; Jiao AL; Tsai LT; Tenen DE; Cole L; Palmer K; Ephraim A; Leaf RK; Nahas M; Apel A; Bar-Natan M; Jain S; McMasters M; Mendez L; Arnason J; Raby BA; Slack F; Kufe D; Avigan D
Leukemia; 2017 Dec; 31(12):2780-2790. PubMed ID: 28555079
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of chemosensitivity by simultaneously silencing of Mcl-1 and Survivin genes using small interfering RNA in human myelomonocytic leukaemia.
Jafarlou M; Shanehbandi D; Dehghan P; Mansoori B; Othman F; Baradaran B
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):1792-1798. PubMed ID: 29113504
[TBL] [Abstract][Full Text] [Related]
10. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia.
Pyzer AR; Stroopinsky D; Rajabi H; Washington A; Tagde A; Coll M; Fung J; Bryant MP; Cole L; Palmer K; Somaiya P; Karp Leaf R; Nahas M; Apel A; Jain S; McMasters M; Mendez L; Levine J; Joyce R; Arnason J; Pandolfi PP; Kufe D; Rosenblatt J; Avigan D
Blood; 2017 Mar; 129(13):1791-1801. PubMed ID: 28126925
[TBL] [Abstract][Full Text] [Related]
11. Survivin' Acute Myeloid Leukaemia-A Personalised Target for inv(16) Patients.
Greiner J; Brown E; Bullinger L; Hills RK; Morris V; Döhner H; Mills KI; Guinn BA
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638823
[TBL] [Abstract][Full Text] [Related]
12. Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.
Smith AM; Little EB; Zivanovic A; Hong P; Liu AK; Burow R; Stinson C; Hallahan AR; Moore AS
Leuk Res; 2015 Apr; 39(4):435-44. PubMed ID: 25659731
[TBL] [Abstract][Full Text] [Related]
13. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
[TBL] [Abstract][Full Text] [Related]
14. LncRNA MAGI2-AS3 inhibits the self-renewal of leukaemic stem cells by promoting TET2-dependent DNA demethylation of the LRIG1 promoter in acute myeloid leukaemia.
Chen L; Fan X; Zhu J; Chen X; Liu Y; Zhou H
RNA Biol; 2020 Jun; 17(6):784-793. PubMed ID: 32174258
[TBL] [Abstract][Full Text] [Related]
15. Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway.
Zhang Y; Chen HX; Zhou SY; Wang SX; Zheng K; Xu DD; Liu YT; Wang XY; Wang X; Yan HZ; Zhang L; Liu QY; Chen WQ; Wang YF
Mol Cancer; 2015 Mar; 14():56. PubMed ID: 25890196
[TBL] [Abstract][Full Text] [Related]
16. MUC1-C drives MYC in multiple myeloma.
Tagde A; Rajabi H; Bouillez A; Alam M; Gali R; Bailey S; Tai YT; Hideshima T; Anderson K; Avigan D; Kufe D
Blood; 2016 May; 127(21):2587-97. PubMed ID: 26907633
[TBL] [Abstract][Full Text] [Related]
17. Targeting miR-193a-AML1-ETO-β-catenin axis by melatonin suppresses the self-renewal of leukaemia stem cells in leukaemia with t (8;21) translocation.
Zhou B; Ye H; Xing C; Liang B; Li H; Chen L; Huang X; Wu Y; Gao S
J Cell Mol Med; 2019 Aug; 23(8):5246-5258. PubMed ID: 31119862
[TBL] [Abstract][Full Text] [Related]
18. CUEDC2, a novel interacting partner of the SOCS1 protein, plays important roles in the leukaemogenesis of acute myeloid leukaemia.
Wu QY; Zhu YY; Liu Y; Wei F; Tong YX; Cao J; Zhou P; Niu MS; Li ZY; Zeng LY; Li F; Xu KL
Cell Death Dis; 2018 Jul; 9(7):774. PubMed ID: 29991678
[TBL] [Abstract][Full Text] [Related]
19. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
20. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia.
Huang J; Lyu H; Wang J; Liu B
Cancer Lett; 2015 Oct; 366(2):160-72. PubMed ID: 26123662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
